Delivery of IL-15/IL-15Rα to tumor cells effectively mediated anti-tumor activity and sensitized the tumor microenvironment (TME) for therapy with αPD-L1 therapeutics, mainly by impacting NK cells. The gene discussed is IL15RA; the disease is neoplasm.